NP5 and 0QOI Related Headlines
Go Back- Newron meets with FDA over US trial enrollment hold
- Newron Provides Update Following Type A Meeting With the FDA
- Newron Pharmaceuticals to Participate in June Investor Conferences
- Newron Reports a Pause of Enrollment of New Study Participants in US Centers of ENIGMA-TRS 2 Study
- Newron Presents 2025 Financial Results and Provides 2026 Outlook
- Newron Announces Agreement With the European Investment Bank (EIB) to Extend the Near-Term Tranche Repayment Dates of Its 2018 Finance Contract
- Newron proposes two new board directors ahead of April meeting
- Newron Announces Nominations to Its Board of Directors at Upcoming Annual General Meeting
- Newron Secures Up to EUR 38 Million to Advance Phase III Evenamide Program
- Newron Notes Publication Highlighting Clinically Meaningful Benefits of Evenamide as an Adjunctive Treatment in Schizophrenia
- EA Pharma, a subsidiary of Eisai, Announces the Initiation of its Phase III Clinical Trial with Evenamide, a Novel Treatment for Schizophrenia, in Japan
- Newron Further Expands Intellectual Property Portfolio for Evenamide with New EU Composition of Matter Patent
- Newron to Host Investor and Partnering Meetings During the J.P. Morgan Healthcare Conference Week
- Newron Announces the US Initiation of Its ENIGMA-TRS 2 Phase III Global Clinical Study With Evenamide as an Add-On Therapy for Patients With Treatment-Resistant Schizophrenia (TRS)
- Newron to Present New Analyses From and Updates on its Clinical Program Evaluating Evenamide as an Add-on Treatment for Schizophrenia at the 38th European College of Neuropsychopharmacology (ECNP) Con
- Newron presents H1 2025 results and provides business update
- Newron to present data and updates on its clinical program evaluating evenamide as an add-on treatment for schizophrenia at the 2025 World Congress of Biological Psychiatry (WCBP)
NP5 and 0QOI Related Press Releases
Go Back- Newron Provides Update Following Type A Meeting With the FDA
- Newron Pharmaceuticals to Participate in June Investor Conferences
- Newron Reports a Pause of Enrollment of New Study Participants in US Centers of ENIGMA-TRS 2 Study
- Newron Presents 2025 Financial Results and Provides 2026 Outlook
- Newron Announces Agreement With the European Investment Bank (EIB) to Extend the Near-Term Tranche Repayment Dates of Its 2018 Finance Contract
- Newron Announces Nominations to Its Board of Directors at Upcoming Annual General Meeting
- Newron Secures Up to EUR 38 Million to Advance Phase III Evenamide Program
- Newron Notes Publication Highlighting Clinically Meaningful Benefits of Evenamide as an Adjunctive Treatment in Schizophrenia
- EA Pharma, a subsidiary of Eisai, Announces the Initiation of its Phase III Clinical Trial with Evenamide, a Novel Treatment for Schizophrenia, in Japan
- Newron Further Expands Intellectual Property Portfolio for Evenamide with New EU Composition of Matter Patent
- Newron to Host Investor and Partnering Meetings During the J.P. Morgan Healthcare Conference Week
- Newron Announces the US Initiation of Its ENIGMA-TRS 2 Phase III Global Clinical Study With Evenamide as an Add-On Therapy for Patients With Treatment-Resistant Schizophrenia (TRS)
- Newron to Present New Analyses From and Updates on its Clinical Program Evaluating Evenamide as an Add-on Treatment for Schizophrenia at the 38th European College of Neuropsychopharmacology (ECNP) Con
- Newron presents H1 2025 results and provides business update
- Newron to present data and updates on its clinical program evaluating evenamide as an add-on treatment for schizophrenia at the 2025 World Congress of Biological Psychiatry (WCBP)
